{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:00:23Z","timestamp":1790676023930,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T00:00:00Z","timestamp":1603843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2016R1A5A2012284"],"award-info":[{"award-number":["NRF-2016R1A5A2012284"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["NRF-2018R1A2B6008455"],"award-info":[{"award-number":["NRF-2018R1A2B6008455"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00262-020-02759-6","type":"journal-article","created":{"date-parts":[[2020,10,28]],"date-time":"2020-10-28T08:02:32Z","timestamp":1603872152000},"page":"1075-1088","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Improvement of DC-based vaccines using adjuvant TLR4-binding 60S acidic ribosomal protein P2 and immune checkpoint inhibitors"],"prefix":"10.1007","volume":"70","author":[{"given":"Gun-Young","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Seob","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Dong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9853-913X","authenticated-orcid":false,"given":"Tae Heung","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeong-Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,28]]},"reference":[{"issue":"1","key":"2759_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, Cueto FJ, Mujal AM, Melero I, Krummel MF, Sancho D (2020) Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol 20(1):7\u201324. https:\/\/doi.org\/10.1038\/s41577-019-0210-z","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"2759_CR2","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nri1372","volume":"4","author":"S-Y Seong","year":"2004","unstructured":"Seong S-Y, Matzinger P (2004) Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4(6):469\u2013478. https:\/\/doi.org\/10.1038\/nri1372","journal-title":"Nat Rev Immunol"},{"key":"2759_CR3","doi-asserted-by":"publisher","first-page":"920","DOI":"10.3390\/v3060920","volume":"3","author":"MRK Thompson","year":"2011","unstructured":"Thompson MRK, Kurt-Jones JJ, Fitzgerald EA (2011) Pattern recognition receptors and the innate immune response to viral infection. Viruses 3:920\u2013940","journal-title":"Viruses"},{"issue":"6","key":"2759_CR4","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","volume":"140","author":"O Takeuchi","year":"2010","unstructured":"Takeuchi O, Akira S (2010) Pattern recognition receptors and inflammation. Cell 140(6):805\u2013820. https:\/\/doi.org\/10.1016\/j.cell.2010.01.022","journal-title":"Cell"},{"issue":"2","key":"2759_CR5","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1365-2567.2004.01976.x","volume":"113","author":"EM Palsson-McDermott","year":"2004","unstructured":"Palsson-McDermott EM, O\u2019Neill LA (2004) Signal transduction by the lipopolysaccharide receptor, toll-like receptor-4. Immunology 113(2):153\u2013162. https:\/\/doi.org\/10.1111\/j.1365-2567.2004.01976.x","journal-title":"Immunology"},{"issue":"1","key":"2759_CR6","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1084\/jem.20141318","volume":"212","author":"H Yang","year":"2015","unstructured":"Yang H, Wang H, Ju Z, Ragab AA, Lundback P, Long W, Valdes-Ferrer SI, He M, Pribis JP, Li J, Lu B, Gero D, Szabo C, Antoine DJ, Harris HE, Golenbock DT, Meng J, Roth J, Chavan SS, Andersson U, Billiar TR, Tracey KJ, Al-Abed Y (2015) MD-2 is required for disulfide HMGB1-dependent TLR4 signaling. J Exp Med 212(1):5\u201314. https:\/\/doi.org\/10.1084\/jem.20141318","journal-title":"J Exp Med"},{"issue":"2","key":"2759_CR7","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/s1470-2045(14)71199-4","volume":"16","author":"AJ Breugom","year":"2015","unstructured":"Breugom AJ, Swets M, Bosset JF, Collette L, Sainato A, Cionini L, Glynne-Jones R, Counsell N, Bastiaannet E, van den Broek CB, Liefers GJ, Putter H, van de Velde CJ (2015) Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16(2):200\u2013207. https:\/\/doi.org\/10.1016\/s1470-2045(14)71199-4","journal-title":"Lancet Oncol"},{"issue":"1","key":"2759_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/cncr.10630","volume":"95","author":"N Carelle","year":"2002","unstructured":"Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D (2002) Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 95(1):155\u2013163. https:\/\/doi.org\/10.1002\/cncr.10630","journal-title":"Cancer"},{"issue":"2","key":"2759_CR9","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cell.2018.09.035","volume":"175","author":"MF Sanmamed","year":"2018","unstructured":"Sanmamed MF, Chen L (2018) a paradigm shift in cancer immunotherapy: from enhancement to normalization. Cell 175(2):313\u2013326. https:\/\/doi.org\/10.1016\/j.cell.2018.09.035","journal-title":"Cell"},{"issue":"4","key":"2759_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrc3258","volume":"12","author":"K Palucka","year":"2012","unstructured":"Palucka K, Banchereau J (2012) Cancer immunotherapy via dendritic cells. Nat Rev Cancer 12(4):265\u2013277. https:\/\/doi.org\/10.1038\/nrc3258","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2759_CR11","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/S0092-8674(01)00455-X","volume":"106","author":"A Lanzavecchia","year":"2001","unstructured":"Lanzavecchia A, Sallusto F (2001) Regulation of T cell immunity by dendritic cells. Cell 106(3):263\u2013266. https:\/\/doi.org\/10.1016\/S0092-8674(01)00455-X","journal-title":"Cell"},{"issue":"2","key":"2759_CR12","doi-asserted-by":"publisher","first-page":"443","DOI":"10.4049\/jimmunol.1701024","volume":"200","author":"PM Santos","year":"2018","unstructured":"Santos PM, Butterfield LH (2018) Dendritic cell-based cancer vaccines. J Immunol 200(2):443. https:\/\/doi.org\/10.4049\/jimmunol.1701024","journal-title":"J Immunol"},{"issue":"11","key":"2759_CR13","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever MA, Higano CS (2011) PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res 17(11):3520. https:\/\/doi.org\/10.1158\/1078-0432.CCR-10-3126","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2759_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50(12):1\u201311. https:\/\/doi.org\/10.1038\/s12276-018-0191-1","journal-title":"Exp Mol Med"},{"issue":"1","key":"2759_CR15","doi-asserted-by":"publisher","first-page":"15732","DOI":"10.1038\/s41598-018-33933-7","volume":"8","author":"A Lopes","year":"2018","unstructured":"Lopes A, Vanvarenberg K, Kos \u0160, Lucas S, Colau D, Van den Eynde B, Pr\u00e9at V, Vandermeulen G (2018) Combination of immune checkpoint blockade with DNA cancer vaccine induces potent anti-tumor immunity against P815 mastocytoma. Sci Rep 8(1):15732. https:\/\/doi.org\/10.1038\/s41598-018-33933-7","journal-title":"Sci Rep"},{"issue":"7","key":"2759_CR16","doi-asserted-by":"publisher","first-page":"821","DOI":"10.2217\/imt-2016-0002","volume":"8","author":"C Kyi","year":"2016","unstructured":"Kyi C, Postow MA (2016) Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy 8(7):821\u2013837. https:\/\/doi.org\/10.2217\/imt-2016-0002","journal-title":"Immunotherapy"},{"key":"2759_CR17","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.3389\/fimmu.2018.02874","volume":"9","author":"NI Ho","year":"2018","unstructured":"Ho NI, Huis I, Veld LGM, Raaijmakers TK, Adema GJ (2018) Adjuvants enhancing cross-presentation by dendritic cells: the key to more effective vaccines? Front Immunol 9:2874\u20132874. https:\/\/doi.org\/10.3389\/fimmu.2018.02874","journal-title":"Front Immunol"},{"issue":"6","key":"2759_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.3109\/15376516.2010.486420","volume":"20","author":"AM Sharifi","year":"2010","unstructured":"Sharifi AM, Hoda FE, Noor AM (2010) Studying the effect of LPS on cytotoxicity and apoptosis in PC12 neuronal cells: role of Bax, Bcl-2, and Caspase-3 protein expression. Toxicol Mech Methods 20(6):316\u2013320. https:\/\/doi.org\/10.3109\/15376516.2010.486420","journal-title":"Toxicol Mech Methods"},{"issue":"1","key":"2759_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1111\/j.1365-2567.2012.03559.x","volume":"136","author":"C Weber","year":"2012","unstructured":"Weber C, M\u00fcller C, Podszuweit A, Montino C, Vollmer J, Forsbach A (2012) Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects). Immunology 136(1):64\u201377. https:\/\/doi.org\/10.1111\/j.1365-2567.2012.03559.x","journal-title":"Immunology"},{"issue":"1","key":"2759_CR20","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s40425-019-0539-7","volume":"7","author":"HJ Park","year":"2019","unstructured":"Park HJ, Jang G-Y, Kim YS, Park JH, Lee SE, Vo M-C, Lee J-J, Han HD, Jung ID, Kang TH, Park Y-M (2019) A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine. J Immunother Cancer 7(1):60\u201360. https:\/\/doi.org\/10.1186\/s40425-019-0539-7","journal-title":"J Immunother Cancer"},{"issue":"9","key":"2759_CR21","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1080\/15548627.2015.1063764","volume":"11","author":"A Artero-Castro","year":"2015","unstructured":"Artero-Castro A, Perez-Alea M, Feliciano A, Leal JA, Genestar M, Castellvi J, Peg V, Ramon YCS, Lleonart ME (2015) Disruption of the ribosomal P complex leads to stress-induced autophagy. Autophagy 11(9):1499\u20131519. https:\/\/doi.org\/10.1080\/15548627.2015.1063764","journal-title":"Autophagy"},{"issue":"8","key":"2759_CR22","doi-asserted-by":"publisher","first-page":"2858","DOI":"10.1158\/0008-5472.can-10-3487","volume":"71","author":"ID Jung","year":"2011","unstructured":"Jung ID, Jeong SK, Lee CM, Noh KT, Heo DR, Shin YK, Yun CH, Koh WJ, Akira S, Whang J, Kim HJ, Park WS, Shin SJ, Park YM (2011) Enhanced efficacy of therapeutic cancer vaccines produced by co-treatment with Mycobacterium tuberculosis heparin-binding hemagglutinin, a novel TLR4 agonist. Cancer Res 71(8):2858\u20132870. https:\/\/doi.org\/10.1158\/0008-5472.can-10-3487","journal-title":"Cancer Res"},{"key":"2759_CR23","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fimmu.2018.00394","volume":"9","author":"M Versteven","year":"2018","unstructured":"Versteven M, Van den Bergh JMJ, Marcq E, Smits ELJ, Van Tendeloo VFI, Hobo W, Lion E (2018) Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer. Front Immunol 9:394\u2013394. https:\/\/doi.org\/10.3389\/fimmu.2018.00394","journal-title":"Front Immunol"},{"issue":"10","key":"2759_CR24","doi-asserted-by":"publisher","first-page":"e0139867","DOI":"10.1371\/journal.pone.0139867","volume":"10","author":"A-M Sponaas","year":"2015","unstructured":"Sponaas A-M, Moharrami NN, Feyzi E, Standal T, Holth Rustad E, Waage A, Sundan A (2015) PDL1 expression on plasma and dendritic cells in myeloma bone marrow suggests benefit of targeted anti PD1-PDL1 therapy. PLoS ONE 10(10):e0139867\u2013e0139867. https:\/\/doi.org\/10.1371\/journal.pone.0139867","journal-title":"PLoS ONE"},{"issue":"5","key":"2759_CR25","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1172\/JCI31205","volume":"117","author":"E Gilboa","year":"2007","unstructured":"Gilboa E (2007) DC-based cancer vaccines. J Clin Investig 117(5):1195\u20131203. https:\/\/doi.org\/10.1172\/JCI31205","journal-title":"J Clin Investig"},{"key":"2759_CR26","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3389\/fimmu.2016.00481","volume":"7","author":"CE Hughes","year":"2016","unstructured":"Hughes CE, Benson RA, Bedaj M, Maffia P (2016) Antigen-presenting cells and antigen presentation in tertiary lymphoid organs. Front Immunol 7:481. https:\/\/doi.org\/10.3389\/fimmu.2016.00481","journal-title":"Front Immunol"},{"issue":"8","key":"2759_CR27","doi-asserted-by":"publisher","first-page":"3253","DOI":"10.1096\/fj.15-271502","volume":"29","author":"F Saupe","year":"2015","unstructured":"Saupe F, Huijbers EJ, Hein T, Femel J, Cedervall J, Olsson AK, Hellman L (2015) Vaccines targeting self-antigens: mechanisms and efficacy-determining parameters. FASEB J Off Pub Am Soc Exp Biol 29(8):3253\u20133262. https:\/\/doi.org\/10.1096\/fj.15-271502","journal-title":"FASEB J Off Pub Am Soc Exp Biol"},{"issue":"1","key":"2759_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/cmr.16.1.1-17.2003","volume":"16","author":"EM Burd","year":"2003","unstructured":"Burd EM (2003) Human papillomavirus and cervical cancer. Clin Microbiol Rev 16(1):1\u201317. https:\/\/doi.org\/10.1128\/cmr.16.1.1-17.2003","journal-title":"Clin Microbiol Rev"},{"key":"2759_CR29","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/j.1600-065X.2008.00622.x","volume":"222","author":"C-F Hung","year":"2008","unstructured":"Hung C-F, Wu TC, Monie A, Roden R (2008) Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev 222:43\u201369. https:\/\/doi.org\/10.1111\/j.1600-065X.2008.00622.x","journal-title":"Immunol Rev"},{"key":"2759_CR30","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.3389\/fimmu.2018.01499","volume":"9","author":"Y Guo","year":"2018","unstructured":"Guo Y, Lei K, Tang L (2018) Neoantigen vaccine delivery for personalized anticancer immunotherapy. Front Immunol 9:1499\u20131499. https:\/\/doi.org\/10.3389\/fimmu.2018.01499","journal-title":"Front Immunol"},{"issue":"1","key":"2759_CR31","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00262-019-02448-z","volume":"69","author":"R Zhang","year":"2020","unstructured":"Zhang R, Yuan F, Shu Y, Tian Y, Zhou B, Yi L, Zhang X, Ding Z, Xu H, Yang L (2020) Personalized neo-antigen-pulsed dendritic cell vaccines show superior immunogenicity to neoantigen-adjuvant vaccines in mouse tumor models. Cancer Immunol Immunother 69(1):135\u2013145. https:\/\/doi.org\/10.1007\/s00262-019-02448-z","journal-title":"Cancer Immunol Immunother"},{"key":"2759_CR32","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.3389\/fimmu.2018.02265","volume":"9","author":"WW van Willigen","year":"2018","unstructured":"van Willigen WW, Bloemendal M, Gerritsen WR, Schreibelt G, de Vries IJM, Bol KF (2018) Dendritic cell cancer therapy: vaccinating the right patient at the right time. Front Immunol 9:2265. https:\/\/doi.org\/10.3389\/fimmu.2018.02265","journal-title":"Front Immunol"},{"issue":"8","key":"2759_CR33","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.it.2017.05.006","volume":"38","author":"AD Garg","year":"2017","unstructured":"Garg AD, Coulie PG, Van den Eynde BJ, Agostinis P (2017) Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol 38(8):577\u2013593. https:\/\/doi.org\/10.1016\/j.it.2017.05.006","journal-title":"Trends Immunol"},{"key":"2759_CR34","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3389\/fimmu.2020.00507","volume":"11","author":"R Dolcetti","year":"2020","unstructured":"Dolcetti R, L\u00f3pez-Soto A, Dal Col J (2020) Editorial: dendritic cell-based immunotherapy in solid and haematologic tumors. Front Immunol 11:507\u2013507. https:\/\/doi.org\/10.3389\/fimmu.2020.00507","journal-title":"Front Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02759-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-020-02759-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-020-02759-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T11:03:01Z","timestamp":1616151781000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-020-02759-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,28]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["2759"],"URL":"https:\/\/doi.org\/10.1007\/s00262-020-02759-6","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,28]]},"assertion":[{"value":"1 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) of Konkuk University (KU18083).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}